NEW YORK – In the oncology field, there has been much focus on understanding the role of tumor mutational burden as a predictive biomarker for immunotherapy amid conflicting findings.
Now, in a study published last week in Nature Communications, a group of researchers has found that two major components of the immunoproteasome are associated with survival in melanoma patients and response to checkpoint inhibitors.